Bifogade filer
Beskrivning
Land | Norge |
---|---|
Lista | OAX Equities |
Sektor | Hälsovård |
Industri | Medicinteknik |
2025-10-10 12:11:13
Oslo, 10 October 2025
Reference is made to the stock exchange announcement by Observe Medical ASA
("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 19 September 2025,
regarding notice of an extraordinary general meeting in connection with a
private placement to be carried out pursuant to an investment agreement entered
into with Songa Capital AS, as announced by the Company on 16 September 2025
(the "Private Placement").
The extraordinary general meeting was held today, on 10 October 2025, at 11:00
hours (CEST).
All resolutions proposed by the Company's board of directors were approved,
including the issuance of 20,000,000 new shares to complete the Private
Placement.
The minutes from the extraordinary general meeting are enclosed hereto and will
also be available on the Company's website www.observemedical.com/investor
-relations.
For further information, please contact:
Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com
About Observe Medical:
Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.
This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.